News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
BIOCYTOGEN (02315.HK) Partner NEOK Bio's Bispecific ADC NEOK002 Approved for US Clinical Trial
BIOCYTOGEN-B (02315.HK) announced that its partner, NEOK Bio, Inc., has recently received approval from the United States Food and Drug Administration for the investigational new d...
Reset
Send
The window will close in 5 seconds
BIOCYTOGEN (02315.HK) Partner NEOK Bio's Bispecific ADC NEOK002 Approved for US Clinical Trial
Close
Recommend
1
Positive
3
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

BIOCYTOGEN-B (02315.HK)  -2.700 (-4.515%)    Short selling $979.53K; Ratio 1.703%   announced that its partner, NEOK Bio, Inc., has recently received approval from the United States Food and Drug Administration for the investigational new drug clinical trial application of NEOK002. NEOK002 is an antibody-drug conjugate ("ADC") targeting EGFR/MUC1, intended for the treatment of solid tumors.

NEOK Bio plans to initiate a Phase I clinical trial in the second quarter of 2026 and expects to release preliminary clinical data in 2027. (hc/w)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.


HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-21 16:25

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.